Literature DB >> 22927522

Progress against solid tumors in danger: the metastatic breast cancer example.

Javier Cortés1, Emiliano Calvo, Antonio González-Martín, Shaheenah Dawood, Antonio Llombart-Cussac, Leticia De Mattos-Arruda, Patricia Gómez, Orlando Silva, Edith A Perez, Hope S Rugo, Ana Lluch, Gabriel N Hortobagyi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22927522      PMCID： PMC6076005          DOI： 10.1200/JCO.2012.41.9580

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  32 in total

1.  Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.

Authors:  Sabine Geiger-Gritsch; Bjoern Stollenwerk; Rebecca Miksad; Beate Guba; Claudia Wild; Uwe Siebert
Journal:  Oncologist       Date:  2010-11-02

2.  Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials.

Authors:  David Miles; Nadia Harbeck; Bernard Escudier; Herbert Hurwitz; Leonard Saltz; Eric Van Cutsem; Jim Cassidy; Barbara Mueller; Florin Sirzén
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

3.  Risk of venous thromboembolism with bevacizumab in cancer patients.

Authors:  Javier Cortes; Cristina Saura; Francesco Atzori
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

Review 4.  Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

Authors:  Edward L Korn; Boris Freidlin; Jeffrey S Abrams
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

5.  Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Authors:  Toni K Choueiri; Erica L Mayer; Youjin Je; Jonathan E Rosenberg; Paul L Nguyen; Georges R Azzi; Joaquim Bellmunt; Harold J Burstein; Fabio A B Schutz
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

6.  The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy.

Authors:  Shaheenah Dawood; Asim Jamal Shaikh; Thomas A Buchholz; Javier Cortes; Massimo Cristofanilli; Sudeep Gupta; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2011-10-05       Impact factor: 6.860

7.  Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Authors:  Javier Cortes; Joyce O'Shaughnessy; David Loesch; Joanne L Blum; Linda T Vahdat; Katarina Petrakova; Philippe Chollet; Alexey Manikas; Veronique Diéras; Thierry Delozier; Vladimir Vladimirov; Fatima Cardoso; Han Koh; Philippe Bougnoux; Corina E Dutcus; Seth Seegobin; Denis Mir; Nicole Meneses; Jantien Wanders; Chris Twelves
Journal:  Lancet       Date:  2011-03-02       Impact factor: 79.321

8.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

9.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Authors:  Stephen Johnston; John Pippen; Xavier Pivot; Mikhail Lichinitser; Saeed Sadeghi; Veronique Dieras; Henry Leonidas Gomez; Gilles Romieu; Alexey Manikhas; M John Kennedy; Michael F Press; Julie Maltzman; Allison Florance; Lisa O'Rourke; Cristina Oliva; Steven Stein; Mark Pegram
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

Review 10.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

Authors:  Shobha Rani Nalluri; David Chu; Roger Keresztes; Xiaolei Zhu; Shenhong Wu
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272
View more
  4 in total

1.  SEOM clinical guidelines for the management of metastatic breast cancer 2013.

Authors:  A Llombart Cussac; J de la Haba Rodríguez; A Ruiz Simón; I Álvarez López; J Cortés Castán
Journal:  Clin Transl Oncol       Date:  2013-10-23       Impact factor: 3.405

2.  Use of bevacizumab as a first-line treatment for metastatic breast cancer.

Authors:  L Manso; F Moreno; R Márquez; B Castelo; A Arcediano; M Arroyo; A I Ballesteros; I Calvo; M J Echarri; S Enrech; A Gómez; R González Del Val; E López-Miranda; M Martín-Angulo; N Martínez-Jañez; C Olier; P Zamora
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

3.  Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials.

Authors:  Sukeshi R Patel; Anand B Karnad; Norma S Ketchum; Brad H Pollock; John Sarantopoulos; Steven Weitman; Devalingam Mahalingam
Journal:  J Gastrointest Oncol       Date:  2014-04

4.  Measures of outcome in metastatic breast cancer: insights from a real-world scenario.

Authors:  Marta Bonotto; Lorenzo Gerratana; Elena Poletto; Pamela Driol; Manuela Giangreco; Stefania Russo; Alessandro M Minisini; Claudia Andreetta; Mauro Mansutti; Federica E Pisa; Gianpiero Fasola; Fabio Puglisi
Journal:  Oncologist       Date:  2014-05-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.